Q1 EPS Estimates for Wave Life Sciences Lowered by B. Riley

Wave Life Sciences Ltd. (NASDAQ:WVE) – B. Riley lowered their Q1 2025 earnings per share (EPS) estimates for shares of Wave Life Sciences in a research report issued on Wednesday, March 5th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of ($0.28) for the quarter, down from their previous forecast of ($0.25). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.98) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.20) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $1.05 EPS.

A number of other analysts have also recently commented on the company. Truist Financial lifted their price objective on Wave Life Sciences from $17.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. Mizuho increased their price objective on shares of Wave Life Sciences from $19.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target on the stock. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Wave Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Price Performance

Shares of Wave Life Sciences stock opened at $9.40 on Friday. The business has a 50 day moving average price of $11.44 and a 200 day moving average price of $11.21. The company has a market capitalization of $1.43 billion, a P/E ratio of -8.47 and a beta of -1.09. Wave Life Sciences has a 1 year low of $4.25 and a 1 year high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 169,025 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 29.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. raised its holdings in shares of Wave Life Sciences by 16.6% in the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company’s stock worth $180,000 after purchasing an additional 2,073 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after purchasing an additional 2,308 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Wave Life Sciences in the 4th quarter worth about $40,000. Kraematon Investment Advisors Inc. lifted its position in shares of Wave Life Sciences by 24.3% in the fourth quarter. Kraematon Investment Advisors Inc. now owns 19,885 shares of the company’s stock worth $246,000 after purchasing an additional 3,885 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its holdings in shares of Wave Life Sciences by 36.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 15,579 shares of the company’s stock worth $193,000 after purchasing an additional 4,120 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.